CardiologyOnline.net

Cardiology Xagena

Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The American Association for Thoracic Surgery ( AATS ) has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation ( POAF ) and f ...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system ( RAAS ) blockade with angiotensin-converting-enzyme inhibit ...


Ventricular fibrillation is one of the most serious complications of acute myocardial infarction, with a high mortality rate. There is a lack of value of rescue thrombolysis in ST-segment elevation my ...


Despite endorsement of Digoxin in clinical practice guidelines, there exist limited data on its safety in atrial fibrillation / atrial flutter. The goal of a study was to evaluate the association o ...


Post-thrombotic syndrome ( PTS ) is a common and burdensome complication of deep venous thrombosis ( DVT ). Previous trials suggesting benefit of elastic compression stockings ( ECS ) to prevent post- ...


Body-mass index ( BMI ) and diabetes mellitus have increased worldwide, whereas global average blood pressure and cholesterol have decreased or remained unchanged in the past three decades. Research ...


The outcome of patients with ruptured abdominal aortic aneurysm ( rAAA ) varies by country. Study of practice differences might allow the formulation of pathways to improve care. Data from the Hosp ...


Four new oral anticoagulants compare favourably with Warfarin ( Coumadin ) for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups nee ...


LCZ696 has shown to be superior to Ace inhibitor Enalapril ( Enapren ) on key endpoints in the largest heart failure study ever done. In PARADIGM-HF patients with heart failure with reduced ejection f ...


Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. Serelaxin is a synthetic versi ...


Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan. The findin ...


Renal denervation ( RDN ) with radiofrequency ablation substantially reduces blood pressure in patients with treatment-resistant hypertension. Researchers have assessed the long-term antihypertensive ...


In final draft guidance NICE ( National Institute for Health and Care Excellence ) has defined which heart devices ( known as implantable cardiac devices ) are the most clinically and cost effective. ...


The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would represent a major clinical advance for prevention and treatment of coronary artery disease. R ...


The aim of a study was to examine mortality and liver disease among patients exposed to Dronedarone ( Multaq ).There has been concern about the safety of Dronedarone, especially for patients with hear ...


It has been investigated whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. A large number of trials compared the diffe ...


Researchers have studied the effect of long term exposure to airborne pollutants on the incidence of acute coronary events in 11 cohorts participating in the European Study of Cohorts for Air Pollutio ...


The objective of a study was to assess whether a strategy of endovascular repair ( if aortic morphology is suitable, open repair if not ) versus open repair reduces early mortality for patients with s ...


Atrial fibrillation is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reduction of recurrence in patients with symptomatic paroxysmal atrial fibrilla ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati